AbbVie Inc. sell WatchMen
Start price
07.04.24
/
50%
€157.00
Target price
07.04.25
-
Performance (%)
-3.39%
End price
02.05.24
€151.68
Summary
This prediction ended on 02.05.24 with a price of €151.68. With a performance of -3.39%, the SELL prediction for AbbVie Inc. by WatchMen was down slightly. WatchMen has a follow-up prediction for AbbVie Inc., but this time predicts that AbbVie Inc. is a Buy. Dividends of €1.46 are taken into consideration when calculating the performance. WatchMen has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | 1.766% | 1.766% |
| iShares Core DAX® | 0.051% | 5.593% |
| iShares Nasdaq 100 | 1.808% | 7.445% |
| iShares Nikkei 225® | 2.181% | 2.815% |
| iShares S&P 500 | 1.040% | 4.975% |